1-(6-乙炔基吡啶-2-基)乙酮 | 874379-35-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(6-乙炔基吡啶-2-基)乙酮
• 英文名称: 2-acetyl-6-ethynylpyridine
• 英文别名: 1-(6-ethynylpyridin-2-yl)ethan-1-one；1-(6-ethynylpyridin-2-yl)ethanone；1-(6-Ethynyl-pyridin-2-yl)-ethanone
• CAS: 874379-35-8
• 化学式: C₉H₇NO
• mdl: MFCD09032141
• 分子量: 145.161
• InChiKey: YJKJIRRZZRDXFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(6-乙炔基吡啶-2-基)乙酮 在 bis(triphenylphosphine)palladium(II)-chloride 四氢吡咯 、 copper(l) iodide 、 二异丙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 24.0h， 生成 1,2-di[6-(1,10-phenanthrolin-2-yl)pyrid-2-yl]ethyne
  参考文献：
  名称：

  Synthetic Approaches to Polypyridyl Bridging Ligands with Proximal Multidentate Binding Sites

  摘要：

  A series of 12 bridging ligands was prepared. These ligands include a central linker appended to two 1,8-naphthyrid-2-yl or two 1,10-phenanthrolin-2-yl units. The linkers include pyridazin-3.6-diyl, 1,8-naphthyrid-2,7-diyl, 2,2'-bipyrid-6,6'-diyl, 1, 10-phenanthrolin-2,9-diyl, 1,2-di(2'-pyrid-6'-yl)ethyne, and 3,6-di(2'-pyrid-6'-yl)pyridazine. The ligands were synthesized from the diacetyl derivative of the central linker by a Friedlander condensation with either 2-aminonicotinaldehyde or 8-amino-7-quinolinecarbaldehyde. The precursor diacetyl derivatives were, in turn, prepared by pathways involving Stille and Sonogashira couplings. Examination of the electronic absorption spectra of the bridging ligands shows the strongest correlation to be between pairs of ligands having the same central linker. Complexation studies will follow.

  DOI：

  10.1021/jo051937r
• 作为产物：
  描述：

  2,6-二溴吡啶 在 bis(triphenylphosphine)palladium(II)-chloride copper(l) iodide 、 正丁基锂 、 四丁基氟化铵 、 二异丙胺 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 为溶剂， 反应 91.0h， 生成 1-(6-乙炔基吡啶-2-基)乙酮
  参考文献：
  名称：

  Synthetic Approaches to Polypyridyl Bridging Ligands with Proximal Multidentate Binding Sites

  摘要：

  A series of 12 bridging ligands was prepared. These ligands include a central linker appended to two 1,8-naphthyrid-2-yl or two 1,10-phenanthrolin-2-yl units. The linkers include pyridazin-3.6-diyl, 1,8-naphthyrid-2,7-diyl, 2,2'-bipyrid-6,6'-diyl, 1, 10-phenanthrolin-2,9-diyl, 1,2-di(2'-pyrid-6'-yl)ethyne, and 3,6-di(2'-pyrid-6'-yl)pyridazine. The ligands were synthesized from the diacetyl derivative of the central linker by a Friedlander condensation with either 2-aminonicotinaldehyde or 8-amino-7-quinolinecarbaldehyde. The precursor diacetyl derivatives were, in turn, prepared by pathways involving Stille and Sonogashira couplings. Examination of the electronic absorption spectra of the bridging ligands shows the strongest correlation to be between pairs of ligands having the same central linker. Complexation studies will follow.

  DOI：

  10.1021/jo051937r

文献信息

• [EN] RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] INHIBITEURS DE RET, COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS ASSOCIÉES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2020114487A1

  公开（公告）日：2020-06-11

  Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

  本文提供了一种RET抑制剂，其药物组合物以及其用途。具体而言，提供了具有化学式（I）或其立体异构体、几何异构体、互变异构体、N-氧化物、溶剂合物、代谢物、药用可接受盐或其前药的化合物。提供了包括该化合物的药物组合物，并且提供了该化合物及其药物组合物的用途，用于制备药物，特别是用于治疗和预防与RET相关的疾病和症状，包括癌症、肠易激综合征以及/或与肠易激综合征相关的疼痛。
• [EN] HYDRAZNE DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS D'HYDRAZINE POUR LE TRAITEMENT DU CANCER
  申请人：UNIV RUTGERS

  公开号：WO2016123253A1

  公开（公告）日：2016-08-04

  The invention provides compounds of formula (I): and salts thereof, wherein ring A, R2, HET, X, n, and R3 have any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for treating cancer using such compounds and salts.

  该发明提供了式（I）的化合物及其盐，其中环A、R2、HET、X、n和R3具有规范中描述的任何含义，以及包含这些化合物和盐的组合物，以及使用这些化合物和盐治疗癌症的方法。
• Hydrazone derivatives for the treatment of cancer
  申请人：RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

  公开号：US10828288B2

  公开（公告）日：2020-11-10

  The invention provides compounds of formula (I): and salts thereof wherein ring A, R2, HET, X, n, and R3 have any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for treating cancer using such compounds and salts.

  本发明提供了式(I)化合物：及其盐，其中环A、R2、HET、X、n和R3具有说明书中描述的任何含义，还提供了包含此类化合物和盐的组合物，以及使用此类化合物和盐治疗癌症的方法。
• HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER
  申请人：RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

  公开号：US20180000806A1

  公开（公告）日：2018-01-04

  The invention provides compounds of formula (I): and salts thereof wherein ring A, R 2 , HET, X, n, and R 3 have any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for treating cancer using such compounds and salts.
• Synthetic Approaches to Polypyridyl Bridging Ligands with Proximal Multidentate Binding Sites
  作者：Ruifa Zong、Dong Wang、Richard Hammitt、Randolph P. Thummel

  DOI：10.1021/jo051937r

  日期：2006.1.1

  A series of 12 bridging ligands was prepared. These ligands include a central linker appended to two 1,8-naphthyrid-2-yl or two 1,10-phenanthrolin-2-yl units. The linkers include pyridazin-3.6-diyl, 1,8-naphthyrid-2,7-diyl, 2,2'-bipyrid-6,6'-diyl, 1, 10-phenanthrolin-2,9-diyl, 1,2-di(2'-pyrid-6'-yl)ethyne, and 3,6-di(2'-pyrid-6'-yl)pyridazine. The ligands were synthesized from the diacetyl derivative of the central linker by a Friedlander condensation with either 2-aminonicotinaldehyde or 8-amino-7-quinolinecarbaldehyde. The precursor diacetyl derivatives were, in turn, prepared by pathways involving Stille and Sonogashira couplings. Examination of the electronic absorption spectra of the bridging ligands shows the strongest correlation to be between pairs of ligands having the same central linker. Complexation studies will follow.